The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Open accessAbstract
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
Authors Task Force Members, Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,096
Self-citationClopidogrel for Coronary Stenting
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citationHamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,062
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C. R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.008 · Cited by 447
Self-citation
Cited by
Sorted by citations
Items 601–700 of 873
Choosing a perspective on mortality with DAPT
Parker, W. A., & Storey, R. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv610 · Cited by 3
Serebruany, V. L., & Tomek, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.114 · Cited by 3
To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
Lowenstern, A. M., & Newby, L. K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007288 · Cited by 3
Age-Stratified Mortality Impact of Atrial Fibrillation in Elderly NSTEMI Patients
Doğanözü, E., Gündoğmuş, P. D., & Aksakal, E. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13010051 · Cited by 2
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Self-citationDuración del tratamiento antiagregante en el síndrome coronario agudo
Bueno, H., & Ferreiro, J. L. (2014) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(14)70102-5 · Cited by 2
Wiviott, S. D., & Steg, P. G. (2015) · Cited by 2
Antiplatelet Therapy And Percutaneous Coronary Interventions
René Hameau, D., Fuensalida, A., Quitral, J., Varela, P. S., Sepúlveda, A. M., Herreros, R. C., Patel, S., & Martı́nez-Rodrı́guez, G. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16666200615144423 · Cited by 2
The Role of Antiplatelet agents in ischemic events
Shreen, S., Uddin, M. B., Ali, S. M., & Sultana, Z. (2021) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v11i4-s.4926 · Cited by 2
Orok, E. N., Adeniyi, F. R., & Akawa, O. B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105139 · Cited by 3
Lu, Y., Wang, C., Chang, S., Hsiao, F., Huang, Y.-C., Huang, Y., Liao, T. E., & Chu, P. (2022) · PubMed Central · doi:10.6515/acs.202207_38(4).20220109a · Cited by 2
Girotra, S. R., Stebbins, A., Wruck, L. M., Marquis‐Gravel, G., Gupta, K., Farrehi, P. M., Benziger, C. P., Effron, M. B., Whittle, J., Muñoz, D., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030385 · Cited by 2
Self-citationIschaemic and haemorrhagic risk distribution in real-life patients with acute coronary syndromes
Weckesser, F., Rivero, M., Conde, D. G., Pérez, G., Zaidel, E. J., Garmendia, C. M., Sabouret, P. F., Trivi, M., & Costabel, J. P. (2024) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2024.2365606 · Cited by 2
Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice
Bauer, T., & Hamm, C. W. (2014) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2014.9.3.164 · Cited by 2
Self-citationNovedades en la evaluación del riesgo hemorrágico del paciente con cardiopatía isquémica
Raposeiras‐Roubín, S., & Ariza‐Solé, A. (2017) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30019-6 · Cited by 2
Viruel, M., Muñoz, F., Garmendia, C. M., Parrilla, L., Ruano, C., Rivero, M., Zaidel, E. J., Lalor, N., Pérez, G., & Costabel, J. P. (2022) · doi:10.7775/rac.v90.i2.20506 · Cited by 2
Gorog, D. A., Farag, M., & Patel, H. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s68391 · Cited by 2
ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
Luca, L. D., Bolognese, L., Valgimigli, M., Ceravolo, R., Danzi, G. B., Piccaluga, E., Rakar, S., Cremonesi, A., Bovenzi, F., Abbate, R., et al. (2014) · European Heart Journal Supplements · doi:10.1093/eurheartj/suu030 · Cited by 2
Use of Novel Antiplatelet Agents in Acute Coronary Syndromes
Luna, M., & Holper, E. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0483-4 · Cited by 2
Síndrome coronario agudo sin elevación del segmento ST
de la Cal, T. S., Román, S. A. C. S., & Gómez, J. L. Z. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70609-7 · Cited by 2
Massberg, S., & Sibbing, D. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0216 · Cited by 2
Ossei‐Gerning, N., & Shivu, G. N. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s59420 · Cited by 2
Singh, V., & Cohen, M. G. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0302-9 · Cited by 2
Use of Antiplatelet Agents in Patients With Atherosclerotic Disease
Acharji, S., Lakshmanadoss, U., Rudziński, W., Stapleton, D. D., & Kaluski, E. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2694 · Cited by 2
P2Y12 Antagonists: Pharmacology, Efficacy and Patient Considerations
Shameem, R., Hamid, M. S., Randhawa, A., Spaccavento, C., & Garatt, K. (2014) · Cited by 2
Eisen, A., & Giugliano, R. P. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000080 · Cited by 2
Moreno, P. (2013) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2013.10.001 · Cited by 2
New Insights for Low Dosing With the New P2Y12 Inhibitors
Silvain, J., Kernéis, M., Collet, J., Montalescot, G., & for the ACTION Study Group (2014) · Circulation Journal · doi:10.1253/circj.cj-14-1166 · Cited by 2
Gómez, J. R. M., Duque, L. N. H., & Palacio, J. J. C. (2015) · Revista Med · doi:10.18359/rmed.1744 · Cited by 2
Rodríguez, F., Harrison, R. W., WOJDYLA, D. M., & Mahaffey, K. W. (2015) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000055 · Cited by 2
Scherillo, M., Cirillo, P. L., Formigli, D., Bonzani, G., Calabrò, P., Capogrosso, P., Farina, R., Lanzillo, T., Mascia, F., Mauro, C., et al. (2016) · Angiology · doi:10.1177/0003319716676721 · Cited by 2
Assessing strategies to improve patient management
Waksman, R. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.210 · Cited by 2
Oral antiplatelet agents for the management of acute coronary syndromes
Gesheff, T. B., & Barbour, C. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12438 · Cited by 2
Thrombozytenhemmung doppelt und für drei zusätzliche Jahre?
Silber, S. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-9389-8 · Cited by 2
Antiplatelet therapy in acute coronary syndrome
Brown, A. J. M., & Austin, D. (2017) · Continuing Cardiology Education · doi:10.1002/cce2.48 · Cited by 2
Perna, G. P., Ravasio, R., & Ricciardelli, A. (2017) · Global & Regional Health Technology Assessment · doi:10.5301/grhta.5000255 · Cited by 2
Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review
Sumner, J. D., Zinser, B., & Smith, A. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017715560 · Cited by 2
Cavallari, I., & Patti, G. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1834-x · Cited by 2
Chua, A., Koo, C. Y., Kristanto, W., Parot, M., Tan, E. S. J., Koh, E. H., Gani, M. B. A., Kojodjojo, P., Han, T., Chan, S., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.22950 · Cited by 2
SCA sans sus ST chez le nonagénaire : expérience du CRAC
Hakim, R., Thuaire, C., Saint‐Etienne, C., Marcollet, P., Chassaing, S., Dequenne, P., Laure, C., Gautier, S., Akkoyun-Farinez, J., Motreff, P., et al. (2018) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2018.09.016 · Cited by 2
Unstable Angina/Non-ST Elevation Myocardial Infarction
Evanchan, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-28328-5_9 · Cited by 2
Elevated Serum Levels of Alkaline Phosphatase and the Risk of Low Responsiveness to Clopidogrel
Ye, Y., Zhao, X., Tu, C., Li, Q., & Zeng, Y. (2020) · International Heart Journal · doi:10.1536/ihj.20-285 · Cited by 2
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_18 · Cited by 2
General Considerations for Neurointerventional Procedures
Harrigan, M. R., & Deveikis, J. P. (2018) · Contemporary medical imaging · doi:10.1007/978-3-319-66779-9_4 · Cited by 2
Frailty in cardiovascular disease: Screening tools
Zão, A., Magalhães, S., & Santos, M. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2018.05.016 · Cited by 2
Selvarajah, A., Tavenier, A. H., Fabris, E., van Leeuwen, M. A. H., & Hermanides, R. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195605 · Cited by 2
Antiplatelet and Anticoagulant Drugs
Ducrocq, G., & Steg, P. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00021-2 · Cited by 2
Silva, K. D., Perera, D., & O’Kane, P. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812615-8.00009-0 · Cited by 2
Prasugrel versus ticagrelor in acute coronary syndromes
Tanajura, L. F., Costa, J. R., Chaves, A. J., Centemero, M. P., & Feres, F. (2021) · Journal of Transcatheter Interventions · doi:10.31160/jotci202129a202016 · Cited by 2
Gimbel, M. E., & ten Berg, J. M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1936498 · Cited by 2
Babeş, E. E. (2021) · FARMACIA · doi:10.31925/farmacia.2021.5.14 · Cited by 2
Viewing Cardiovascular Research Through the Eyes of Past, Present, and Future Generations
Peterson, E. D., & Gaziano, J. M. (2012) · JAMA · doi:10.1001/jama.2012.28743 · Cited by 2
Smoking status and the effects of antiplatelet drugs
Hirschl, M. (2013) · BMJ · doi:10.1136/bmj.f5909 · Cited by 2
Sibbing, D., Groß, L., & Maßberg, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.002 · Cited by 2
Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting DilemmaPreprint
Chaturvedula, S. T., Diver, D. J., & Vashist, A. (2018) · Preprints.org · doi:10.20944/preprints201802.0084.v1 · Cited by 2
Antiplatelet Therapy in Cardiovascular Disease
Schmaier, A. A., & Bhatt, D. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-97873-4_18 · Cited by 2
Self-citationThadani, U., Nguyen, Q., & Han, Y. (2016) · doi:10.1002/9781118965061.ch4 · Cited by 2
De-Escalation of DAPT After ACS
Lee, K. S. S., Chatterjee, A., & Acharya, D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.030 · Cited by 2
Kutcher, S., Flatman, L. K., Haber, R., Dendukuri, N., Dandona, S., & Brophy, J. M. (2023) · medRxiv · doi:10.1101/2023.08.12.23294021 · Cited by 2
P2Y12 inhibitors for acute coronary syndromes: current perspectives
Nawarskas, J. J., Newsome, C. C., Anderson, J. R., & Ahmed, B. (2015) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s69478 · Cited by 1
Karwatowska‐Prokopczuk, E., Lu, L., Yang, J. M., Witztum, J. L., & Tsimikas, S. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02818-6 · Cited by 1
Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo
Ponte-Negretti, C. I., Zaidel, E. J., López-Santi, R., Múnera, A. G., Bryce, A., M, S. N., Espinoza, J., Gaibor, J. C., Valcárcel, Y., Antonio, C. D., et al. (2024) · Archivos de cardiología de México · doi:10.24875/acm.m24000096 · Cited by 4
Switching Platelet P2Y12 Receptor Inhibiting Therapies
Ortega‐Paz, L., Rollini, F., Franchi, F., Sibbing, D., & Angiolillo, D. J. (2024) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2024.11.001 · Cited by 1
Abdulrahim, A. O., Abd-Alhadi, M. J. Y., Mahmoud, H., Sarwar, A., Akram, A., Alvarado, W. J., Sadik, O., Kesireddy, S. R., & Mumtaz, H. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002833 · Cited by 1
Antiplatelet Therapy in Coronary Artery Disease
Laudani, C., Capodanno, D., & Angiolillo, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_9 · Cited by 1
Wang, Y., Fuerte-Hortigon, A., Chetty, S., Garah, M., Sarmiento, R. J., Barber, P. A., Saposnik, G., Lee, D. S., Singnurkar, A., Swartz, R. H., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.358 · Cited by 3
Overview of Antiplatelet Therapy for Acute Coronary Syndrome
Ortega‐Paz, L., Franchi, F., & Angiolillo, D. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11869-2.00013-8 · Cited by 1
Prasugrel should be preferred over ticagrelor in acute coronary syndromes: pros and cons
Angiolillo, D. J., Kastrati, A., Frazzetto, M., & Valgimigli, M. (2026) · EuroIntervention · doi:10.4244/eij-e-26-00004 · Cited by 1
The evolution of dual antiplatelet therapy in patients with coronary artery disease
Simonsson, M., James, S. K., ten Berg, J. M., & Gigante, B. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag107 · Cited by 1
Impact and Diagnosis of Antiplatelet Therapy Resistance in Patients Undergoing Cardiac Surgery
Gašparović, H., Petričević, M., & Biočina, B. (2013) · Drug Development Research · doi:10.1002/ddr.21107 · Cited by 1
Widimský, P., Hricak, V., Jarkovský, J., Zbožínková, Z., Littnerová, S., Klimeš, D., Hýblová, L., & Fraňová, B. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.04.009 · Cited by 1
Classification and definition of acute coronary syndromes - A time for change?
Widimský, P. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.05.003 · Cited by 1
Clopidogrel for Smokers and Aspirin for Nonsmokers?: Not So Fast
Williams, C. D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.52 · Cited by 1
Camuglia, A. C., Waddell-Smith, K. E., Hammett, C. J. K., & Aylward, P. E. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.949647 · Cited by 1
Self-citationSTEMI - The importance of balance between antithrombotic treatment and bleeding risk
Pospíšil, J., Hromádka, M., Bernát, I., & Rokyta, R. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.02.004 · Cited by 1
Risks and benefits of antiplatelet therapies
Khan, N. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.5.236 · Cited by 1
Republished: Antiplatelet therapy for secondary prevention of coronary artery disease
Pilgrim, T., & Windecker, S. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-305399rep · Cited by 1
Medical management of acute coronary syndromes
Ciffone, N. A., & Dokken, B. B. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12457 · Cited by 4
Many shades of grey: seeking the optimal medical therapy of acute coronary syndrome in older people
Paratz, E. D., Nicolaides, S., & Layland, J. J. (2017) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1365 · Cited by 1
Duration of Dual Antiplatelet Therapy in the Post–Acute Coronary Syndrome Patient
Bobadilla, R. V. (2017) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000452 · Cited by 1
Hammett, C. J. K., Amerena, J. V., Brieger, D. B., Sindone, A. P., Thompson, P. L., Worthley, M. I., & Aylward, P. E. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1418175 · Cited by 1
Self-citationPlatelet Inhibition as a Therapeutic Approach in Intravascular Intervention
Ahrens, I., & Bueno, H. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-66224-4_6 · Cited by 1
The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist
Widmer, R. J., Pollak, P. M., Bell, M. R., Gersh, B. J., & Anavekar, N. S. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.016 · Cited by 1
Medizin, D. K. F. K. K., Neumann, F., Byrne, R. A., Gawaz, M., Hoffmeister, H.-M., Schäfer, A., Trenk, D., & Maßberg, S. (2018) · Der Kardiologe · doi:10.1007/s12181-018-0258-1 · Cited by 1
Yin, E. B., Nguyen, H. D., Kamat, I., Bayat, M., & Alam, M. (2018) · Europe PMC (PubMed Central) · Cited by 1
Non-ST-Elevation Acute Coronary Syndromes
Ghaffari, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00028-4 · Cited by 1
Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data
Maragkoudakis, S., Katsi, V. K., Melidonis, A. J., Σουλαϊδόπουλος, Σ., Kolovou, G. D., Papazafeiropoulou, A., Trikkalinou, A., Toutouzas, K. P., & Tsioufis, K. P. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220103091236 · Cited by 1
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_18 · Cited by 1
Berger, M., Baaten, C. C. F. M. J., Noels, H., Marx, N., & Schütt, K. S. (2022) · Herz · doi:10.1007/s00059-022-05129-3 · Cited by 1
Peng, C.-H., Huang, T.-P., Chen, Y., Hsu, C., & Cheng, I.-L. (2022) · PubMed Central · doi:10.6515/acs.202207_38(4).20220319a · Cited by 1
Research Progress on Related Genes of Clopidogrel Resistance
李, 倩. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133549 · Cited by 1
Chang, H.-H., Hung, C., Chen, Y., & Fang, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237221 · Cited by 1
General Considerations for Neurointerventional Procedures
Harrigan, M. R., & Deveikis, J. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-946-4_4 · Cited by 1
Assessing post-treatment platelet reactivity: a focus on patient selection and setting
Laine, M., Frère, C., Ronsin, O., Gaubert, M., Toesca, R., Bessereau, J., Michelet, P., Gramond, C., Helal, O., Paganelli, F. F., et al. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.820440 · Cited by 1
Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease
Proscia, C., Nusca, A., Mega, S., Melfi, R., & Sciascio, G. D. (2015) · Interventional Cardiology · doi:10.2217/ica.15.9 · Cited by 1
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Chew, D. P., Hasenfuss, G. P., et al. (2015) · Cited by 1
An update on management of the patient presenting with non-ST-elevation acute coronary syndromes
Kaliyadan, A. G., Savage, M. P., Ruggiero, N. J., & Fischman, D. L. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1179119 · Cited by 1
Antiplatelet Therapy for Percutaneous Coronary Intervention: Something Old and Something New
Gaglia, M. A. (2017) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-017-0533-x · Cited by 1
Thrombozytenaggregationshemmer bei koronarer, zerebraler und peripherer Makroangiopathie
Halbach, M., & Baldus, S. E. (2018) · Der Internist · doi:10.1007/s00108-017-0362-5 · Cited by 1
Antiagregación plaquetaria dual en enfermedad coronaria
Vásquez, S. H., Vesga, B., & Hernández, H. J. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.11.017 · Cited by 1
Metadata
- Authors
- Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
- Affiliations
- Duke Medical Center (US)
- University of Alberta (CA)
- Duke University (US)
- St. Michael's Hospital (CA)
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- National Taiwan University (TW)
- Eli Lilly (United States) (US)
- Flinders University (AU)
- ORCID
- Roe, Matthew T.
- Armstrong, Paul W.
- Fox, Keith A.A.
- White, Harvey D.
- Prabhakaran, Dorairaj
- Goodman, Shaun G.
- Cornel, Jan H.
- Bhatt, Deepak L.
- Clemmensen, Peter
- Ardissino, Diego
- Boden, William E.
- Gurbel, Paul A.
- McGuire, Darren K.
- Leiva-Pons, Jose L.
- Parkhomenko, Alexander
- Gottlieb, Shmuel
- Hamm, Christian
- Goudev, Assen R.
- Oto, Ali
- Aylward, Philip E.
- Huber, Kurt
- Hochman, Judith S.
- Ohman, E. Magnus
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-04
- Volume
- 367
- Issue
- 14
- Pages
- 1297-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2109577952
- Cited by
- 874
- References
- 18
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
- FWCI
- 71.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Helsinn
- Boston Scientific Corporation
- Boston VA Research Institute
- Regeneron Pharmaceuticals
- Amarin Corporation
- Medicines Company
- Regado Biosciences
- Eisai
- Astellas Pharma
- Servier
- Genentech
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
